Xpovio (selinexor)

News alerts, weekly reports and conference planners

Company:

Antengene, FORUS Therap, Jiangsu Hansoh Pharma, Karyopharm, Menarini, NeoPharm

Drug class:

XPO1 inhibitor

Related drugs:

‹

›

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	selinexor Sensitive: A1 - Approval selinexor Sensitive : A1	selinexor Sensitive: A1 - Approval selinexor Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	selinexor Sensitive: A1 - Approval selinexor Sensitive : A1	selinexor Sensitive: A1 - Approval selinexor Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	selinexor + pomalidomide Sensitive: A2 - Guideline selinexor + pomalidomide Sensitive : A2	selinexor + pomalidomide Sensitive: A2 - Guideline selinexor + pomalidomide Sensitive : A2
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	selinexor + daratumumab Sensitive: A2 - Guideline selinexor + daratumumab Sensitive : A2	selinexor + daratumumab Sensitive: A2 - Guideline selinexor + daratumumab Sensitive : A2
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	selinexor + carfilzomib Sensitive: A2 - Guideline selinexor + carfilzomib Sensitive : A2	selinexor + carfilzomib Sensitive: A2 - Guideline selinexor + carfilzomib Sensitive : A2
Chr del(17p)	Multiple Myeloma	Chr del(17p)	Multiple Myeloma	bortezomib + selinexor Sensitive: B - Late Trials bortezomib + selinexor Sensitive : B	bortezomib + selinexor Sensitive: B - Late Trials bortezomib + selinexor Sensitive : B
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	selinexor Sensitive: B - Late Trials selinexor Sensitive : B	selinexor Sensitive: B - Late Trials selinexor Sensitive : B
No biomarker	Liposarcoma	No biomarker	Liposarcoma	selinexor Sensitive: B - Late Trials selinexor Sensitive : B	selinexor Sensitive: B - Late Trials selinexor Sensitive : B
GRM1 overexpression	Liposarcoma	GRM1 overexpression	Liposarcoma	selinexor Sensitive: B - Late Trials selinexor Sensitive : B	selinexor Sensitive: B - Late Trials selinexor Sensitive : B
CALB1 underexpression	Liposarcoma	CALB1 underexpression	Liposarcoma	selinexor Sensitive: B - Late Trials selinexor Sensitive : B	selinexor Sensitive: B - Late Trials selinexor Sensitive : B
CALB1 deletion	Liposarcoma	CALB1 deletion	Liposarcoma	selinexor Sensitive: B - Late Trials selinexor Sensitive : B	selinexor Sensitive: B - Late Trials selinexor Sensitive : B
TP53 wild-type	Endometrial Cancer	TP53 wild-type	Endometrial Cancer	selinexor Sensitive: B - Late Trials selinexor Sensitive : B	selinexor Sensitive: B - Late Trials selinexor Sensitive : B
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	selinexor Sensitive: C2 – Inclusion Criteria selinexor Sensitive : C2	selinexor Sensitive: C2 – Inclusion Criteria selinexor Sensitive : C2
NRAS mutation	Multiple Myeloma	NRAS mutation	Multiple Myeloma	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3
RAS mutation	Multiple Myeloma	RAS mutation	Multiple Myeloma	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3
KRAS mutation	Multiple Myeloma	KRAS mutation	Multiple Myeloma	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3
IDH2 R172K	Acute Myelogenous Leukemia	IDH2 R172K	Acute Myelogenous Leukemia	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	pembrolizumab + selinexor Sensitive: C3 – Early Trials pembrolizumab + selinexor Sensitive : C3	pembrolizumab + selinexor Sensitive: C3 – Early Trials pembrolizumab + selinexor Sensitive : C3
RAS mutation	Colorectal Cancer	RAS mutation	Colorectal Cancer	pembrolizumab + selinexor Sensitive: C3 – Early Trials pembrolizumab + selinexor Sensitive : C3	pembrolizumab + selinexor Sensitive: C3 – Early Trials pembrolizumab + selinexor Sensitive : C3
NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	pembrolizumab + selinexor Sensitive: C3 – Early Trials pembrolizumab + selinexor Sensitive : C3	pembrolizumab + selinexor Sensitive: C3 – Early Trials pembrolizumab + selinexor Sensitive : C3
Chr del(17p)	Multiple Myeloma	Chr del(17p)	Multiple Myeloma	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3
DOCK8 mutation	Glioblastoma	DOCK8 mutation	Glioblastoma	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3
EP400 mutation	Glioblastoma	EP400 mutation	Glioblastoma	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3
PDX1 mutation	Glioblastoma	PDX1 mutation	Glioblastoma	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	venetoclax + selinexor Sensitive: C3 – Early Trials venetoclax + selinexor Sensitive : C3	venetoclax + selinexor Sensitive: C3 – Early Trials venetoclax + selinexor Sensitive : C3
PTGS2 expression	Rectal Cancer	PTGS2 expression	Rectal Cancer	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3
CD177 expression	Rectal Cancer	CD177 expression	Rectal Cancer	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3
SF3B1 K666N	Chronic Myeloid Leukemia	SF3B1 K666N	Chronic Myeloid Leukemia	venetoclax + selinexor Sensitive: D – Preclinical venetoclax + selinexor Sensitive : D	venetoclax + selinexor Sensitive: D – Preclinical venetoclax + selinexor Sensitive : D
SF3B1 K666N	B Acute Lymphoblastic Leukemia	SF3B1 K666N	B Acute Lymphoblastic Leukemia	venetoclax + selinexor Sensitive: D – Preclinical venetoclax + selinexor Sensitive : D	venetoclax + selinexor Sensitive: D – Preclinical venetoclax + selinexor Sensitive : D
SF3B1 K666N	B Acute Lymphoblastic Leukemia	SF3B1 K666N	B Acute Lymphoblastic Leukemia	selinexor Sensitive: D – Preclinical selinexor Sensitive : D	selinexor Sensitive: D – Preclinical selinexor Sensitive : D
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	selinexor + MRTX1257 Sensitive: D – Preclinical selinexor + MRTX1257 Sensitive : D	selinexor + MRTX1257 Sensitive: D – Preclinical selinexor + MRTX1257 Sensitive : D

Xpovio (selinexor)

Associations
(47)

Associations
(47)

Xpovio (selinexor)

Associations(47)

Associations(47)

Associations
(47)

Associations
(47)